$HGEN
Just something interesting from BARDA's Strategic Plan for 2022-2026
https://t.co/pdN3anCMOx...
Pg12:
"Achieving FDA approval of two threat-agnostic and host-directed therapeutics for severe
disease by targeting potential organ damage”
We've been playing "Whack-A-Mole" with new SARS-2 variants.
Elegant, anti-fragile approaches are necessary moving forward. It's worth noting the boneyard of *No Longer Supported/Authorized* treatments on BARDA's webpage:
C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 ‘LIVE-AIR’ trial https://t.co/WfCPZ5krb2
Congrats @humanigen! It is fantastic that NIH wants to work with you now on Long Covid. What a fantastic opportunity! Keep up the great work! $hgen #lenzilumab
https://t.co/K78dp5demc
@MGuido8523@LemonDropRealty@humanigen@NIH I don’t think there needs to be criticism. The article says they are in talks. I’m not saying they signed a deal, I’m saying congratulations for being recognized. It’s a big first step. They also have reason to expect it would help with long Covid
@Neophius@Esurien11 I hear you bud. I am very fortunate to be in the position I am in at 26. I lost quite a bit on HGEN but just like you and all the other bulls, I believe in the company which keeps me coming back for more. So it will be the stupidest thing I’ve done, or smartest. Time will tell
@Neophius@Esurien11 CEO wrote a message to investors separate from the PR and said he expects data in the middle of July… not sure why he would go out of his way, and put his word on the line if he didn’t really feel that way. Nothing to gain or lose. So if they get TLD this week.. you know.
@Neophius@Esurien11 I guess my game plan is to grow my August position, next week, and keep my July options. If it happens next week, I will have eggs in both baskets. I am really hopeful of next week, but only 5 days left… I’m watching ADIL. They released a PR with data lock 2 days before us.